Hua Medicine of Shanghai reported that its lead program, HMS5552, a novel oral glucokinase activator (GKA) treatment for Type 2 diabetes, produced a surprising 1% HbA1c average reduction in patients' blood glucose levels after only 4 weeks of treatment. The positive data were part of a China Phase Ic trial. Hua said the drug candidate also showed an excellent tolerability and safety profile with low risk of hypoglycemia or gastrointestinal discomfort. Hua has already begun a China Phase II trial of the drug.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
